ASYMCHEM

Tianjin China

Oligonucleotide Capacity Expansion

To accelerate commercialization and meet surging market demands, Asymchem has successfully commissioned **two new oligonucleotide production** lines at its Tianjin facility.

This expansion boosts total annual capacity to **180 mol/year**. Operating under strict cGMP compliance, the new lines feature **industry-leading automated synthesis** and **purification systems** designed to deliver the rigorous batch-to-batch consistency and high purity required for late-stage clinical and commercial supply.

By **shortening lead times, reducing production costs**, and **strengthening supply chain security**, this upgrade positions Asymchem to seamlessly drive oligonucleotide programs from initial R&D through to full commercialization.

Global ESG and Sustainability Recognition

Asymchem's corporate governance and sustainable operational strategies have earned formal validation in the **S&P Global Sustainability Yearbook 2026**.

Global Distinction

Named an "**Industry Mover**" globally, reflecting a significant upward trajectory in the Corporate Sustainability Assessment (CSA).



Regional Ranking

Ranked within the **Top 10%** of all evaluated companies in China.



These accolades underscore Asymchem's ongoing commitment to reducing Process Mass Intensity (PMI) and maintaining robust, world-class ESG management practices.

ASYMCHEM

UK SANDWICH

Enhanced Biocatalysis Capabilities Propel Biomanufacturing Innovation

Asymchem Sandwich site is proud to have **added biocatalysis** to its workflow offering this quarter, expanding our ability to evaluate and develop more sustainable synthetic routes for our clients.

The introduction of this capability has been supported by **Asymchem's Center of Synthetic Biology Technology (CSBT)**, helping to establish the foundations for biocatalysis activities at the Sandwich site while strengthening connections across the wider Asymchem network.

The new workflows have already been applied to client programmes:

In April, **high-throughput biocatalysis screening** formed part of a complex route scouting study, with approximately 150 enzymes screened across two enzyme families to rapidly assess potential biotransformations and generate proof-of-concept data.

Biocatalysis is now being utilised within an ongoing process chemistry project, where **enzyme-enabled approaches** are being evaluated alongside more traditional synthetic strategies.

Looking ahead, the site has additional enzyme families ready for validation, together with screening kits that can support rapid proof-of-concept studies, enabling clients to quickly assess the feasibility of biocatalytic solutions within their development programmes.